IP Library › Granted Patent US 12,667,573
Granted Patent B2
US 12,667,573 · App. 17/435,830 · Granted Jun 30, 2026

Compounds, compositions, and methods for the treatment of disease

Inventors: Radhakrishnan P. Iyer (Shrewsbury, MA); Seetharamaiyer Padmanabhan (Lexington, MA); Subramanian Baskaran (Shrewsbury, MA); Anjaneyulu Sheri (Shrewsbury, MA); Dillon Cleary (Norton, MA); Ron Mastrolia (Raynham, MA); Shenghua Zhou (Shrewsbury, MA); Sreerupa Challa (Shrewsbury, MA); Rayomand H. Gimi (Chelmsford, MA); Vishal Nair (Norwood, MA); Leena Praba Suppiah (Edmond, OK)
Assignee: invoX Pharma Limited
A61K31/52A61K31/437A61K31/519A61K31/5377A61K31/675A61P37/06C07D471/04C07D473/00C07D473/40C07D487/04C07D519/00C07F9/65616
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,667,573
App. No.
17/435,830
Filed
Sep 2, 2021
Granted
Jun 30, 2026
Kind
B2
Art Unit
1624
USPC
514/81
Abstract

Disclosed are compounds and compositions for inhibiting the expression of a pattern recognition receptor (e.g., STING), and methods of use thereof.

Claims (69)

1 . A compound of formula I:

or a pharmaceutically acceptable salt thereof;

wherein

M is Cl or F;

Z is SR 1 , SO 2 R 1 , or N(R 1 )(R 2 )

R 1 and R 2 are each independently H or alkyl;

R 3 is H, alkyl, methyl, haloalkyl, chloromethyl, alkyloxyalkyl, methoxymethyl, hydroxyalkyl, hydroxymethyl, aminoalkyl, diethylamino, aryl, phenyl, alkynyl, ethynyl, alkyne substituted with cycloalkyl, heterocyclylalkyl or morpholinylalkyl;

L 1 is C 7 -C 15 alkyl;

each R 4 is independently halo, CN, SR 7 , OR 7 , NHCOR 7 , NR 8 CO 2 R 7 , N(R 7 )(R 8 ), COR 7 , CO 2 R 7 , OC(O)R 7 , CON(R 7 )(R 8 ), heteroaryl, or heterocyclyl;

R 7 and R 8 are each independently selected from the group consisting of hydrogen, and alkyl; and

n is an integer from 0-18.

2 . The compound of claim 1 , wherein M is Cl.

3 . The compound of claim 1 , wherein Z is SO 2 R 1 .

4 . The compound of claim 1 , wherein R 1 is methyl, ethyl, isopropyl, or hexyl.

5 . The compound of claim 1 , wherein L 1 is C 7 alkylenyl, C 9 alkylenyl, C 10 alkylenyl, or C 15 alkylenyl.

6 . The compound of claim 1 , wherein each R 4 is independently CO 2 R 7 , COR 7 , heterocyclyl, OR 7 , heteroaryl, or CON(R 7 )(R 8 ).

7 . The compound of claim 1 , wherein each R 4 is independently CO 2 R 7 , heterocyclyl, or COR 7 .

8 . The compound of claim 1 , wherein n is 0, 1, or 2.

9 . A compound selected from the group consisting of:

Compound

Number

Structure

9

24

28

69

74

96

97

109

111

112

114

118

121

122

124

125

128

131

132

133

134

135

136

137

138

139

140

142

143

144

145

146

147

148

149

150

152

158

159

160

162

164

165

167

168

10 . A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable excipient.

11 . A pharmaceutical composition, comprising a compound of claim 9 and a pharmaceutically acceptable excipient.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2024
From: F-STAR THERAPEUTICS, INC.
To: INVOX PHARMA LIMITED
Reel/Frame 068859/0948 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2022
From: SPEROVIE BIOSCIENCES, INC.
To: F-STAR THERAPEUTICS, INC.
Reel/Frame 058643/0595 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2022
From: CLEARY, DILLON; SUPPIAH, LEENA; IYER, RADHAKRISHNAN P.; MASTROLIA, RON; BASKARAN, SUBRAMANIAN; CHALLA, SREERUPA; GIMI, RAYOMAND H.; NAIR, VISHAL; PADMANABHAN, SEETHARAMAIYER; SHERI, ANJANEYULU; ZHOU, SHENGHUA
To: SPEROVIE BIOSCIENCES, INC.
Reel/Frame 058725/0069 →
Continuity (3)
Provisional Application 62879178 · Jul 26, 2019
Provisional Application 62814025 · Mar 5, 2019
Related Publication 20220168309A1 · Jun 2, 2022
References Cited (30)
US 5994361A · Penney et al. · 1999 [cited by applicant]
US 6110923A · Ely · 2000 [cited by applicant]
US 7238700B2 · Palle et al. · 2007 [cited by applicant]
US 20130039933A1 · Barber · 2013 [cited by applicant]
WO WO2008130581A1 · 2008 [cited by applicant]
WO WO2010019392A1 · 2010 [cited by applicant]
WO WO2012167053A1 · 2012 [cited by applicant]
WO WO2013157562A1 · 2013 [cited by applicant]
WO WO2015075598A1 · 2015 [cited by applicant]
WO WO2015137887A1 · 2015 [cited by applicant]
WO 2016120305A1 · 2016 [cited by applicant]
WO WO2019165032A1 · 2019 [cited by applicant]
WO WO2019195063A1 · 2019 [cited by applicant]
WO WO2019195124A1 · 2019 [cited by applicant]
WO WO2020010092A1 · 2020 [cited by applicant]
WO WO2020181050A1 · 2020 [cited by applicant]
Quy et al. (Medicines, (2019), 6(1), 20, pp. 1-13). [cited by examiner]
PubChem-CID: 86302595 Create Date: Dec. 31, 2014, pp. 1-9. [cited by applicant]
PubChem-CID: 13247039 Create Date Feb. 8, 2007, pp. 1-7. [cited by applicant]
PubChem-CID: 91623209 Create Date Mar. 19, 2015, pp. 1-11. [cited by applicant]
PubChem-CID: 57642832 Create Date Aug. 19, 2012, pp. 1-10. [cited by applicant]
Haag et al., “Targeting STING with covalent small-molecule inhibitors” Nature, Jul. 4, 2018, pp. 269-273, vol. 559, No. 7713. [cited by applicant]
Quy et al., “Xanthine oxidase inhibitory potential”, Medicines, Jan. 29, 2019, p. 1. [cited by applicant]
Singh et al., “Studies on nucleosides Part XIII. Synthesis and antiviral activity of acyclic analogues of spongosine”, Indian Journal of Chemistry, 258: 823-827 (1986). [cited by applicant]
Haag et al., “Targeting STING with covalent small-molecule inhibitors.” Nature 559.7713 (2018): 269-273. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/021120 mailed May 20, 2020. [cited by applicant]
PubChem Database CID=13247039, <https://pubchem.ncbi.nlm.nih.gov/compound/13247039> Create Date: Feb. 8, 2007 (Feb. 8, 2007) pp. 1-7; p. 2, structure. [cited by applicant]
PubChem Database CID=57642832, <https://pubchem.ncbi.nlm.nih.gov/compound/57642832> Create Date: Aug. 19, 2012 (Aug. 19, 2012) pp. 1-11; p. 2, structure. [cited by applicant]
PubChem Database CID=86302595, <https://pubchem.ncbi.nlm.nih.gov/compound/86302595> Create Date: Dec. 31, 2014 (Dec. 31, 2014) pp. 1-8; p. 2, structure. [cited by applicant]
PubChem Database CID=91623209, <https://pubchem.ncbi.nlm.nih.gov/compound/91623209> Create Date: Mar. 19, 2015 (Mar. 19, 2015) pp. 1-12; p. 2, structure. [cited by applicant]